Teva Pharmaceutical Industries

Analysis: Teva Pharmaceuticals is bogged down by legal issues, fails to kick-start growth

08.11.20 | Sophie Shulman

For foreign companies, understanding China’s annual plans is critical

12.10.20 | Tslil Kleiman

Teva is recruiting Israeli academia to help produce its next breakthrough drug

13.09.20 | CTech

A renaissance of entrepreneurship and innovation is our chance to withstand the Covid-19 challenge

23.08.20 | Assaf Weiss

Teva Gets Fresh Cash, Fresh Woes

04.02.18 | Dror Reich

Following U.S. Bribe Settlement, Teva to Pay $22 Million Fine in Israel

15.01.18 | Tomer Ganon

Moody’s Downgrades Teva Bond Rating to “Junk”

14.01.18 | Lilach Baumer

After Announcing Restructuring Plan, Teva's Board of Directors Takes Paycut

11.01.18 | Lilach Baumer

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18 | Lilach Baumer

Teva CEO to Netanyahu: Layoffs will Proceed as Planned

19.12.17 | Omri Milman

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17 | Lilach Baumer

Teva Might Have Been Better Off as a Smaller Company, new CEO Says

17.12.17 | Dror Reich

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17 | Lior Gutman, Omri Milman and Micky Grunfeld

Once Future CEO Could have Taken Teva on a Different Path

14.12.17 | Lilach Baumer, Golan Hazani, and Orr Hirschauge

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17 | Dror Reich

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17 | Dror Reich and Sefi Krupsky

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17 | Lilach Baumer

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17 | Dror Reich

Teva’s Stock Jumps Following Report on Planned Cuts

10.12.17 | Dror Reich and Lilach Baumer

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17 | Anat Rouah

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17 | Golan Hazani

New Teva CEO Kåre Schultz to Relocate to Israel

17.10.17 | Golan Hazani

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17 | Lilach Baumer

The Ten Challenges Facing Teva's New CEO

12.09.17 | Sophie Shulman

Teva Sells IUD Business for $1.1 Billion

12.09.17 | Lilach Baumer

Teva Appoints Lundbeck's Schultz as CEO

11.09.17 | Dror Reich and Micky Grunfeld